Prospective, Randomized, Controlled, Clinical Study on Tolerability and Efficacy of hMG-IBSA
A Prospective, Randomized, Controlled Clinical Study on the Assessment of Tolerability and of Clinical Efficacy of MERIONAL® (hMG-IBSA) Administered Subcutaneously Versus MERIONALâ Administered Intramuscularly in Women Undergoing Controlled Ovarian Hyperstimulation (COH) in an ART Programme (IVF)
Sponsor: IBSA Institut Biochimique SA
This PHASE3 trial investigates Infertility and is currently completed. IBSA Institut Biochimique SA leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2017 — Jan 2021 [monthly]
Completed PHASE3
First recorded
Dec 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- IBSA Institut Biochimique SA
For direct contact, visit the study record on ClinicalTrials.gov .